Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2009 December;57(6) > Minerva Cardioangiologica 2009 December;57(6):761-72





A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752




Minerva Cardioangiologica 2009 December;57(6):761-72

language: English

Rational of the use of aliskiren in hypertension and beyond

Westermann D., Savvatis K., Schultheiss H. -P., Tschöpe C.

Department of Cardiology and Pneumology,Charité School of Medicine, Campus Benjamin Franklin, Berlin, Germany


Arterial hypertension is an independent risk factor for cardiovascular diseases and one of the major causes for mortality worldwide. Drugs, that control hypertension effectively are therefore needed to reduce hypertension induced morbidity and mortality. The inhibition of the renin-angiotensin-aldosterone-system (RAAS) is one target to control blood pressure in these patients. The new direct renin inhibitor aliskiren is one new substance on the market to inhibit the RAAS effectively by suppression of the plasma renin activity, which inhibits the RAAS at its rate-limiting step. Therefore, aliskiren in monotherapy and in combination might yield beneficial effects for the patients. Nevertheless, blood pressure lowering has to be combined with a reduction of target organ damage for all drug classes prescribed to patients with hypertension. Therefore, we review here the major effects of this new drug not only in regard to hypertension but also in regard to target organ damage reduction and possible changes in morbidity and mortality, which future trials will investigate.

top of page

Publication History

Cite this article as

Corresponding author e-mail